These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 35635264)
1. Nationwide trends and outcomes of neoadjuvant chemotherapy in pancreatic cancer - an analysis of the Swedish national pancreatic cancer registry. Sternby H; Andersson B Scand J Gastroenterol; 2022 Nov; 57(11):1361-1366. PubMed ID: 35635264 [TBL] [Abstract][Full Text] [Related]
2. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis. Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer: The Actual Spectrum and Clinical Burden of Postoperative Complications. Marchegiani G; Andrianello S; Nessi C; Sandini M; Maggino L; Malleo G; Paiella S; Polati E; Bassi C; Salvia R Ann Surg Oncol; 2018 Mar; 25(3):626-637. PubMed ID: 29214453 [TBL] [Abstract][Full Text] [Related]
4. Examining neoadjuvant treatment candidates in resectable pancreatic cancer based on tumor-vessel interactions and CA 19-9 levels: a retrospective cohort study. Jung HS; Han Y; Yun WG; Cho YJ; Lee M; Lee DH; Kwon W; Jang JY Int J Surg; 2024 May; 110(5):2883-2893. PubMed ID: 38376856 [TBL] [Abstract][Full Text] [Related]
5. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma. Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385 [TBL] [Abstract][Full Text] [Related]
6. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344 [TBL] [Abstract][Full Text] [Related]
7. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma. Dhir M; Zenati MS; Hamad A; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH Ann Surg Oncol; 2018 Jul; 25(7):1896-1903. PubMed ID: 29761331 [TBL] [Abstract][Full Text] [Related]
8. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy. Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659 [TBL] [Abstract][Full Text] [Related]
9. Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma. Qiao G; Fong ZV; Bolm L; Fernandez Del-Castillo C; Ferrone CR; Servin-Rojas M; Pathak P; Lau-Min K; Allen JN; Blaszkowsky LS; Clark JW; Parikh AR; Ryan DP; Weekes CD; Roberts HM; Wo JY; Hong TS; Lillemoe KD; Qadan M Ann Surg; 2024 Jul; 280(1):118-125. PubMed ID: 37830225 [TBL] [Abstract][Full Text] [Related]
10. Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. Ivey GD; Shoucair S; Delitto DJ; Habib JR; Kinny-Köster B; Shubert CR; Lafaro KJ; Cameron JL; Burns WR; Burkhart RA; Thompson EL; Narang A; Zheng L; Wolfgang CL; He J World J Surg; 2022 Nov; 46(11):2751-2759. PubMed ID: 35861852 [TBL] [Abstract][Full Text] [Related]
11. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience. Rangelova E; Wefer A; Persson S; Valente R; Tanaka K; Orsini N; Segersvärd R; Arnelo U; Del Chiaro M Ann Surg; 2021 Mar; 273(3):579-586. PubMed ID: 30946073 [TBL] [Abstract][Full Text] [Related]
12. Intention to treat outcomes among patients with pancreatic cancer treated using International Study Group on Pancreatic Surgery recommended pathways for resectable and borderline resectable disease. Kamarajah SK; Chatzizacharias N; Hodson J; Marcon F; Kalisvaart M; Punia P; Ting Ma Y; Dasari B; Marudanayagam R; Sutcliffe RP; Muiesan P; Mirza DF; Isaac J; Roberts KJ ANZ J Surg; 2021 Jul; 91(7-8):1549-1557. PubMed ID: 33576568 [TBL] [Abstract][Full Text] [Related]
13. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study. Lof S; Korrel M; van Hilst J; Alseidi A; Balzano G; Boggi U; Butturini G; Casadei R; Dokmak S; Edwin B; Falconi M; Keck T; Malleo G; de Pastena M; Tomazic A; Wilmink H; Zerbi A; Besselink MG; Abu Hilal M; Ann Surg Oncol; 2020 Jun; 27(6):1986-1996. PubMed ID: 31848815 [TBL] [Abstract][Full Text] [Related]
14. Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancreatic Consortium. Ogobuiro I; Collier AL; Khan K; de Castro Silva I; Kwon D; Wilson GC; Schwartz PB; Parikh AA; Hammill C; Kim HJ; Kooby DA; Abbott D; Maithel SK; Snyder RA; Ahmad SA; Merchant NB; Datta J Ann Surg Oncol; 2023 Mar; 30(3):1485-1494. PubMed ID: 36316508 [TBL] [Abstract][Full Text] [Related]
15. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy. Blair AB; Rosati LM; Rezaee N; Gemenetzis G; Zheng L; Hruban RH; Cameron JL; Weiss MJ; Wolfgang CL; Herman JM; He J Surgery; 2018 May; 163(5):1090-1096. PubMed ID: 29395234 [TBL] [Abstract][Full Text] [Related]
16. Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy. Cools KS; Sanoff HK; Kim HJ; Yeh JJ; Stitzenberg KB J Surg Oncol; 2018 Sep; 118(3):455-462. PubMed ID: 30114330 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer. Murthy P; Zenati MS; Al Abbas AI; Rieser CJ; Bahary N; Lotze MT; Zeh HJ; Zureikat AH; Boone BA Ann Surg Oncol; 2020 Mar; 27(3):898-906. PubMed ID: 31792715 [TBL] [Abstract][Full Text] [Related]
18. Impact of Neoadjuvant Therapy for Pancreatic Cancer: Transatlantic Trend and Postoperative Outcomes Analysis. Davis CH; Augustinus S; de Graaf N; Wellner UF; Johansen K; Andersson B; Beane JD; Björnsson B; Busch OR; Gleeson EM; van Santvoort HC; Tingstedt B; Williamsson C; Keck T; Besselink MG; Koerkamp BG; Pitt HA; J Am Coll Surg; 2024 Apr; 238(4):613-621. PubMed ID: 38224148 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan. Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421 [TBL] [Abstract][Full Text] [Related]